Systemic AA amyloidosis is a complication of various inflammatory diseases including Crohn's disease (CD). Amyloid nephropathy is the most common clinical presentation of AA amyloidosis leading to renal failure, and affected patients often require hemodialysis and ultimately renal transplantation. We herein report the successful use of infliximab as maintenance therapy for amyloid nephropathy in a patient with CD. In the present patient, surgical treatment and infliximab infusion immediately induced a remission of CD, and scheduled infliximab therapy successfully maintained the patient's stable condition for three years, with a significant decrease in the serum creatinine level. © 2013 The Japanese Society of Internal Medicine.
CITATION STYLE
Tada, Y., Ishihara, S., Ito, T., Matsui, K., Sonoyama, H., Oka, A., … Kinoshita, Y. (2013). Successful use of maintenance infliximab for nephropathy in a patient with secondary amyloidosis complicating Crohn’s disease. Internal Medicine, 52(17), 1899–1902. https://doi.org/10.2169/internalmedicine.52.0340
Mendeley helps you to discover research relevant for your work.